Literature DB >> 21717207

As time goes by?: the fallacy of thrombolysis in STEMI networks.

Wolfgang von Scheidt1, Christian Thilo.   

Abstract

Primary percutaneous coronary intervention (PPCI) is superior to thrombolysis (TL) as reperfusion therapy in ST-elevation myocardial infarction (STEMI). TL is a rapidly available, but semi-effective therapy (effective reperfusion in 50% of patients only), whereas PPCI is a potentially delayed, but highly effective therapy (effective reperfusion in >90%). Since TL loses its efficacy beyond 2-3 h after symptom onset, it is a significant reperfusion alternative to PPCI in early presenters only. The individual decision to treat an early presenter with PPCI or TL requires the evaluation of the time delay between potential start of TL or PPCI, the PCI-related delay (PRD). PRD is greatest, if TL is given in the prehospital setting. Until now, prehospital TL as the most rapidly available reperfusion strategy has failed to demonstrate any prognostic or even any other relevant benefit compared to PPCI in any subgroup of patients, even with time delays for PPCI of up to several hours. On average, a median PRD of at least 90-120 min can be considered a time corridor of prognostic superiority of PPCI over TL. This is already achieved in contemporary registries and myocardial infarction networks.Therefore, the efforts should not focus on the implementation of a dual reperfusion strategy (PPCI, and prehospital TL in selected cases) in established or upcoming myocardial infarction networks, but concentrate on the availability of PPCI in less than 2 h. TL, as rapid as possible, i.e. prehospital, is a vital treatment option in case of non-existing PPCI facilities within a median time limit of 2 h or even more, a scenario not existing or easily to eliminate in European countries by implementing well organized myocardial infarction networks. This is the mission to be accomplished.

Entities:  

Mesh:

Year:  2011        PMID: 21717207     DOI: 10.1007/s00392-011-0332-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  56 in total

1.  Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction.

Authors:  Erik Björklund; Ulf Stenestrand; Johan Lindbäck; Leif Svensson; Lars Wallentin; Bertil Lindahl
Journal:  Eur Heart J       Date:  2006-04-19       Impact factor: 29.983

2.  Impact of minimising door-to-balloon times in ST-elevation myocardial infarction to less than 30 min on outcome: an analysis over an 8-year period in a tertiary care centre.

Authors:  Ulrike M Müller; Ingo Eitel; Kristina Eckrich; Sandra Erbs; Axel Linke; Sven Möbius-Winkler; Meinhard Mende; Gerhard C Schuler; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2010-10-24       Impact factor: 5.460

3.  Strategies for reducing the door-to-balloon time in acute myocardial infarction.

Authors:  Elizabeth H Bradley; Jeph Herrin; Yongfei Wang; Barbara A Barton; Tashonna R Webster; Jennifer A Mattera; Sarah A Roumanis; Jeptha P Curtis; Brahmajee K Nallamothu; David J Magid; Robert L McNamara; Janet Parkosewich; Jerod M Loeb; Harlan M Krumholz
Journal:  N Engl J Med       Date:  2006-11-13       Impact factor: 91.245

4.  In-hospital time to treatment of patients with acute ST elevation myocardial infarction treated with primary angioplasty: determinants and outcome. Results from the registry of percutaneous coronary interventions in acute myocardial infarction of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte.

Authors:  R Zahn; A Vogt; U Zeymer; A K Gitt; K Seidl; M Gottwik; M A Weber; W Niederer; B Mödl; H-J Engel; U Tebbe; J Senges
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

Review 5.  Acceptable reperfusion delay to prefer primary angioplasty over fibrin-specific thrombolytic therapy is affected (mainly) by the patient's mortality risk: 1 h does not fit all.

Authors:  Giuseppe Tarantini; Renato Razzolini; Massimo Napodano; Claudio Bilato; Angelo Ramondo; Sabino Iliceto
Journal:  Eur Heart J       Date:  2009-11-27       Impact factor: 29.983

6.  Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up.

Authors:  Eric Bonnefoy; Philippe Gabriel Steg; Florent Boutitie; Pierre-Yves Dubien; Frédéric Lapostolle; Jérome Roncalli; Frederic Dissait; Gérald Vanzetto; Alain Leizorowicz; Gilbert Kirkorian; C Mercier; E P McFadden; P Touboul
Journal:  Eur Heart J       Date:  2009-05-08       Impact factor: 29.983

Review 7.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

8.  Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction).

Authors:  Ellen Bøhmer; Pavel Hoffmann; Michael Abdelnoor; Harald Arnesen; Sigrun Halvorsen
Journal:  J Am Coll Cardiol       Date:  2009-09-10       Impact factor: 24.094

9.  Reperfusion rate and inhospital mortality of patients with ST segment elevation myocardial infarction diagnosed already in the prehospital phase: results of the German Prehospital Myocardial Infarction Registry (PREMIR).

Authors:  Uwe Zeymer; Hans-Richard Arntz; Burkhardt Dirks; Klaus Ellinger; Harald Genzwürker; Lutz Nibbe; Ulrich Tebbe; Jochen Senges; Steffen Schneider
Journal:  Resuscitation       Date:  2009-01-22       Impact factor: 5.262

Review 10.  The pharmaco-invasive approach to STEMI: when should fibrinolytic-treated patients go to the "cath lab"?

Authors:  J J Edmond; C P Juergens; J K French
Journal:  Postgrad Med J       Date:  2009-06       Impact factor: 2.401

View more
  5 in total

1.  Reperfusion therapy and mortality in octogenarian STEMI patients: results from the Belgian STEMI registry.

Authors:  Els H Vandecasteele; Marc De Buyzere; Sofie Gevaert; Antoine de Meester; Carl Convens; Philippe Dubois; Jean Boland; Peter Sinnaeve; Herbert De Raedt; Pascal Vranckx; Patrick Coussement; Patrick Evrard; Christophe Beauloye; Marc Renard; Marc J Claeys
Journal:  Clin Res Cardiol       Date:  2013-07-26       Impact factor: 5.460

2.  Interhospital transfer due to failed prehospital diagnosis for primary percutaneous coronary intervention: an observational study on incidence, predictors, and clinical impact.

Authors:  Karim D Mahmoud; Youlan L Gu; Maarten W Nijsten; Ronald de Vos; Wybe Nieuwland; Felix Zijlstra; Hans L Hillege; Iwan C van der Horst; Bart Jgl de Smet
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-06

Review 3.  Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.

Authors:  T Steiner; M Böhm; M Dichgans; H-C Diener; C Ell; M Endres; C Epple; M Grond; U Laufs; G Nickenig; H Riess; J Röther; P D Schellinger; M Spannagl; R Veltkamp
Journal:  Clin Res Cardiol       Date:  2013-05-14       Impact factor: 5.460

4.  TNF-α, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention.

Authors:  Eva S Kehmeier; Wolfgang Lepper; Martina Kropp; Christian Heiss; Ulrike Hendgen-Cotta; Jan Balzer; Mirja Neizel; Christian Meyer; Marc W Merx; Pablo E Verde; Christian Ohmann; Gerd Heusch; Malte Kelm; Tienush Rassaf
Journal:  Clin Res Cardiol       Date:  2012-05-06       Impact factor: 5.460

5.  Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.

Authors:  Jens Wiebe; Helge Möllmann; Astrid Most; Oliver Dörr; Kay Weipert; Johannes Rixe; Christoph Liebetrau; Albrecht Elsässer; Stephan Achenbach; Christian Hamm; Holger Nef
Journal:  Clin Res Cardiol       Date:  2013-10-18       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.